Sotalol - PDFSEARCH.IO - Document Search Engine

Sotalol
Results: 15

#	Item
11	® BETAPACE AF (sotalol HCl[removed]To minimize the risk of induced arrhythmia, patients initiated or re-initiated on Betapace AF® should be placed for a minimum of three days (on their maintenance dose) in a facility Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2011-08-24 15:12:02 Cardiology Antiarrhythmic agents Potassium channel blockers Cardiac electrophysiology Alcohols Torsades de pointes Amiodarone Long QT syndrome Sotalol Cardiac dysrhythmia Chemistry Circulatory system
12	Kansas Medical Assistance Program P O Box 3571 Topeka, KS[removed]Provider[removed]Beneficiary[removed] Add to Reading List Source URL: www.kdheks.gov Language: English - Date: 2014-05-05 14:30:52 Organic chemistry Propranolol Carvedilol Bisoprolol Metoprolol Medicaid Sotalol Chemistry Beta blockers Alcohols
13	BETAPACE® (sotalol HCl) To minimize the risk of induced arrhythmia, patients initiated or reinitiated on Betapace® should be placed for a minimum of three days (on their maintenance dose) in a facility that can provide Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2011-08-24 14:44:33 Cardiology Antiarrhythmic agents Potassium channel blockers Cardiac electrophysiology Amines Torsades de pointes Ventricular tachycardia Long QT syndrome Flecainide Chemistry Cardiac dysrhythmia Medicine
14	BETAPACE (sotalol HCl) To minimize the risk of induced arrhythmia, patients initiated or reinitiated on Betapace should be placed for a minimum of three days (on their maintenance dose) in a facility that can provide car Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2011-02-04 14:55:20 Cardiology Antiarrhythmic agents Potassium channel blockers Cardiac electrophysiology Sodium channel blockers Torsades de pointes Ventricular tachycardia Long QT syndrome Amiodarone Cardiac dysrhythmia Medicine Chemistry
15	June 14, 2013 Press release: Mitsubishi Tanabe Pharma Corporation Approval for Additional Indication for Atrial Fibrillation (Tachycardiac ) MAINTATE® Tablets: Selective β1 Blocker Add to Reading List Source URL: www.mt-pharma.co.jp Language: English - Date: 2013-06-13 04:40:59 Cardiology Chemistry Beta blockers Atrial fibrillation Bisoprolol Antiarrhythmic agents Systole Sotalol Cardiac dysrhythmia Alcohols Circulatory system

UPDATE